Clinical trials: Respiratory Infection
Tachycardia, Dyspnea
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC).
- Conditions
- Tachycardia, Dyspnea, COVID-19
- Trial name
- PEACE (NCT05096884)
- Testing
- Metoprolol Succinate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hackensack Meridian Health
Influenza, Respiratory Tract Infections
Patient Portal - Flu Reminder Recall
This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive…
- Conditions
- Influenza, Respiratory Tract Infections, Vaccines
- Trial name
- NCT03666026
- Testing
- 1 MyChart R/R, 2 MyChart R/R, 3 MyChart R/R
- Where
- United States
- Volunteers
- 164,205 people
- Sponsor
- University of California, Los Angeles
Influenza
A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
FLU-v is a vaccine that aims to protect against a wide range of flu viruses. The purpose of this study is to measure the immune responses induced by FLU-v vaccine.
- Trial name
- NCT02962908
- Testing
- FLU-v, adjuvanted FLU-v, Saline
- Where
- Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
Chronic Obstructive Pulmonary Disease, Heart Failure
PATient Navigator to rEduce Readmissions
Staying out of the hospital is valued by patients and their caregivers. Their interests converge with those of hospitals now that high 30-day readmission rates for some conditions place hospitals at risk for financial penalties…
- Conditions
- Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction
- Trial name
- PArTNER (NCT02114515)
- Testing
- Hospital usual care, Navigator intervention, Peer-led telephone support line
- Where
- United States
- Volunteers
- 1,029 people
- Sponsor
- University of Illinois Chicago
Covid19, Health Care Seeking Behavior
New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations
This mixed methods study evaluates the effectiveness and cost of a healthcare worker focused outreach intervention strategy versus community organization led outreach to explore contextual factors (individual, family, and…
- Conditions
- Covid19, Health Care Seeking Behavior, Health Behavior
- Trial name
- NCT04766333
- Testing
- Healthcare Worker Focused Outreach, Community Organization Led Outreach
- Where
- United States
- Volunteers
- 2,017 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19, SARS-CoV 2
Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in…
- Trial name
- NCT04365153
- Testing
- Canakinumab Injection 600mg, Canakinumab Injection 300mg
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- The Cleveland Clinic
Influenza
Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.
The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a more immunogenic and effective response compared with conventional influenza vaccines in elderly and adults.
- Trial name
- NCT02255279
- Testing
- Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29), Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).
- Where
- 3 sites in Mexico
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT05736861
- Testing
- Ivermectin
- Where
- 87 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- Susanna Naggie, MD
COVID-19
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19
The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof…
- Trial name
- NCT05164120
- Testing
- Belnacasan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MedStar Health
Influenza
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the safety and tolerability in patients with…
- Trial name
- NCT01032837
- Testing
- Oseltamivir
- Where
- 100 sites in United States
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Tuberculosis, Pulmonary
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
This study is a multiple-arm, multiple-stage (MAMS), phase 2, open label, randomized, controlled clinical trial that will compare the efficacy and safety of four experimental four drug regimens with a standard control regimen in…
- Trial name
- NCT01785186
- Testing
- SQ109, Rifampicin, Moxifloxacin
- Where
- 7 sites in South Africa, Tanzania
- Volunteers
- 365 people
- Sponsor
- Michael Hoelscher
Influenza, Human
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza…
- Trial name
- NCT05540522
- Testing
- Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine
- Where
- 321 sites in United States, Argentina and 4 more
- Volunteers
- 45,789 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT04576702
- Testing
- Investigational aIIV4c, IIV4c, aIIV4
- Where
- 21 sites in United States
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
This Phase 2, randomized, observer-blind, antigen and adjuvant dose-ranging Clinical study is evaluating different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT04782323
- Testing
- aQII-1, aQII-3 Investigational, aQII-6 Investigational
- Where
- 30 sites in Australia, New Zealand and 2 more
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK…
- Trial name
- NCT01196988
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 59 sites in United States, Czechia and 3 more
- Volunteers
- 3,027 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Pulmonary Complications, COVID-19
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019…
- Trial name
- NCT04382586
- Testing
- Zanubrutinib, Supportive Care
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- BeiGene
Adolescent HPV Vaccine, Adolescent Influenza Vaccine
4 Pillars Toolkit for Adolescent Vaccination
The purpose of this study is to test whether or not the 4 Pillars Immunization Toolkit increases adolescent vaccination rates, particularly influenza and human papillomavirus (HPV) but also tetanus, diphtheria and pertussis…
- Trial name
- NCT02165722
- Testing
- 4 Pillars Toolkit
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Influenza
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus…
- Trial name
- CAPSTONE 1 (NCT02954354)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 1,436 people
- Sponsor
- Shionogi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.